AI Article Synopsis
- 1L immunotherapy has shown better overall survival rates in metastatic melanoma compared to 1L targeted therapy, especially for eligible patients.
- A study in Finland (2014-2021) compared outcomes of patients treated with 1L immunotherapy vs. 1L targeted therapy, highlighting significant differences in survival rates and baseline characteristics.
- Patients receiving 1L immunotherapy had fewer severe baseline conditions and higher 2-year survival rates (60.3-63.5%) compared to those on 1L targeted therapy (33.8%).
Article Abstract
First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT). Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 wild type, 85 -mutated) or 1L TT (143 -mutated) for MM in Finland during 2014-2021. Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy. Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14796694.2024.2403329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!